SCHEMBL4677799

SCHEMBL4677799

O=C(Cc1ccc(Cc2ccc(C(F)(F)F)cc2)o1)C(=O)c1nc[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.34
ALDH1A1 P00352 1/20 0.34
VKORC1 Q9BQB6 1/20 0.34
KDM5A P29375 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
PTPN1 P18031 4/20 0.33
PTPN2 P17706 2/20 0.33
PTPN6 P29350 2/20 0.33
HDAC1 Q13547 2/20 0.33
PIK3CA P42336 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221462 0.87 CYP1A2 (0.35) ALDH1A1MEN1LMNAMAPTKMT2A
SCHEMBL4677064 0.87 NR3C2 (0.39) PTPN1HDAC1MEN1LMNAMAPT
SCHEMBL4672900 0.87 HTT (0.33) ALDH1A1PTPN1SMN1; SMN2
Hydrochloric Acid SCHEMBL6853681 0.86 CYP1A2 (0.34) ALDH1A1MEN1LMNAMAPTKMT2A
SCHEMBL4678602 0.86 SMN1; SMN2 (0.38) ALDH1A1LMNAMAPTKMT2ASMN1; SMN2
SCHEMBL4671677 0.86 LMNA (0.33) ALDH1A1HDAC1LMNAMAPTHDAC6
SCHEMBL4676639 0.85 HTT (0.31) ALDH1A1
SCHEMBL4672875 0.85 ALDH1A1 (0.40) ALDH1A1MEN1LMNAMAPTKMT2A
SCHEMBL4678966 0.85 PTGER1 (0.35) HDAC1HDAC8
SCHEMBL4671982 0.84 SRD5A2 (0.35) SRD5A2ALDH1A1KDM5AKDM4CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SRD5A2 371/4885ALDH1A1 980/4885VKORC1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.